CLPTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
ClearPoint Neuro, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$9.17+0.10 (+1.10%)
Close on Oct 19, 2026
- Market cap
- $276.63M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
61.4%−9.7 pts over 5 years
Operating margin
-65.4%−16.9 pts over 5 years
Net margin
-69.1%−16.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +17.8% | +21.6% | +23.6% | +23.2% | |
| Gross profit | +18.7% | +18.8% | +20.0% | +24.2% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 589.6% | -194.8% | -95.6% | |
| Return on assets | -93.1% | -32.7% | -37.3% | |
| Current ratio | 2.02 | 7.96 | 5.91 | |
| Debt to equity | – | – | 1.75 | |
| Net debt to EBITDA | – | – | -0.14× | |
| Interest coverage | -7.1× | -4.3× | -10.1× | |
| Inventory turnover | 1.5× | 1.1× | 1.9× | |
| Capex to revenue | 1.8% | 0.3% | 1.4% | |
| Diluted shares | 3M | 16M | 28M |
Where the cash went
Fiscal 2021 to 2025, five years combined
ClearPoint Neuro generated $75.43M from operations and spent $1.94M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$75.43M
Used
$1.94M
Capital expenditure$1.94M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-69.1%
×Asset turnover0.54×
×Equity multiplier2.56×
=Return on equity, FY2025-95.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -69.1% | 0.54× | 2.56× | -95.6% |
| FY2024 | -60.3% | 0.77× | 1.76× | -81.2% |
| FY2023 | -92.2% | 0.49× | 1.69× | -76.1% |
| FY2022 | -80.0% | 0.34× | 1.41× | -38.4% |
| FY2021 | -88.4% | 0.34× | 1.86× | -56.3% |
| FY2020 | -52.9% | 0.62× | 5.95× | -194.8% |
| FY2019 | -49.4% | 1.13× | 3.25× | -181.8% |
| FY2018 | -83.8% | 0.68× | 2.96× | -168.0% |
| FY2017 | -97.1% | 0.69× | 4.20× | -282.6% |
| FY2016 | -140.4% | 0.66× | -6.33× | 589.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$25.54M
- Cash generatingOperating cash flow above zero-$23.90M
- Return on assets improvedROA up on the prior year-44.3% → -65.2%
- Earnings backed by cashOperating cash flow above net income-$23.90M vs -$25.54M
- Less leverageLong-term debt to assets fell0.0% → 50.2%
- Better liquidityCurrent ratio rose3.22 → 5.91
- No dilutionShare count did not rise27M → 28M
- Gross margin improvedGross margin up on the prior year60.92% → 61.38%
- More efficientAsset turnover rose0.74 → 0.94